RxDoctor Payments Data

Edgar Moreno

Physician Assistant · Bakersfield, CANPI 1003381583

Payments from drug & device makers

$6,832in general payments, 2019–2025

Across 215 payments — averaging $31.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Novo Nordisk$735
  • Amgen$720
  • Xeris Pharmaceuticals, Inc.$566
  • Lilly USA, LLC$390
  • Ascensia Diabetes Care US Inc.$298
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$1,34920%
  • Food & beverage$5,35378%
  • Education$1312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,832 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide357$379,558
JardianceEmpagliflozin234$199,861
MounjaroTirzepatide144$150,877
TrulicityDulaglutide132$125,190
RybelsusSemaglutide68$68,093
FarxigaDapagliflozin Propanediol88$64,797
Synjardy XrEmpagliflozin/Metformin Hcl61$48,366
Xigduo XrDapaglifloz Propaned/Metformin49$48,101
SynjardyEmpagliflozin/Metformin Hcl61$46,037
JanuviaSitagliptin Phosphate44$40,724
Fiasp FlextouchInsulin Aspart (Niacinamide)62$32,140
Humalog Kwikpen U-200Insulin Lispro39$30,298
TradjentaLinagliptin36$27,144
Tresiba Flextouch U-200Insulin Degludec56$26,791
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog82$23,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$735$447,651425 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta$68$321,408392 claims
Lilly USA, LLCMounjaro, Trulicity$390$276,067276 claims
AstraZenecaFarxiga$241$64,79788 claims
AbbVieLinzess, Synthroid$144$10,00442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →